 |
|
|
 |
|
Use of OrbusNeich's Genous Stent in a Coronary Bifurcation Setting Is Feasible and Safe, with No Incidence of Late Stent Thrombosis and a Very Low Rate of Repeated Revascularization
Date: December 22, 2011
Client: OrbusNeich
Summary: HONG KONG, Dec. 20, 2011 - OrbusNeich today reported clinical data showing that the Genous Stent is a feasible and safe option for the treatment of bifurcation lesions, with no incidence of late stent thrombosis (ST) and a very low rate of repeat revascularization reported at one year. The data were published in the December issue of Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine.
|
|
|
|
 |
|
MedAssurant Earns CMS Encounter Data Front-End Testing Certification
Date: December 14, 2011
Client: MedAssurant, Inc.
Summary: BOWIE, Md., Dec. 14, 2011 /PRNewswire/ -- MedAssurant, Inc., a leading provider of data-driven healthcare solutions, today announced the successful completion of the Encounter Data Front-End System testing that the Centers for Medicare and Medicaid Services (CMS) is requiring for the submission of Medicare Advantage organization encounter data. With this significant milestone achieved, MedAssurant is certified by CMS to advance to the End-to-End testing and certification phase, which CMS has scheduled to begin on January 3, 2012.
|
|
|
|
 |
|
Putting the ‘M’ Back in M&A
Date: December 13, 2011
Client: BIOCOM
Summary: Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large.
|
|
|
|
 |
|
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date: December 13, 2011
Client: Astellas Pharma Inc.
Summary: San Diego, December 13, 2011 - Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that updated results from an interim analysis of a Phase 2 study of quizartinib (formerly AC220) in acute myeloid leukemia (AML) were presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. Data were also presented from two additional posters: one evaluating the pharmacodynamic effects of quizartinib in a pooled analysis from Phase 1 and Phase 2 studies, and another demonstrating that quizartinib enhances the activity of chemotherapy in an in vivo preclinical model of AML harboring the FLT3-ITD mutation. The findings from those presentations are described below.
|
|
|
|
 |
|
Cellular Dynamics Announces Commercial Launch of iCell Neurons for Neuroscience Drug Discovery
Date: December 13, 2011
Client: Cellular Dynamics International (CDI)
Summary: MADISON, Wis., Dec 13, 2011 - Cellular Dynamics International (CDI) today announced the commercial launch of human iCell Neurons for use in neuroscience drug discovery, neurotoxicity screens, and other health research. This is the first commercial availability of human neurons, or brain cells, created from induced pluripotent stem (iPS) cells in the quantity, quality, and purity required for life science research.
|
|
|
|
 |
|
At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
Date: December 13, 2011
Client: Brinson Patrick
Summary: NEW YORK, Dec. 13, 2011 - Brinson Patrick Securities Corporation, a boutique investment bank specializing in at-the-market (ATM) offerings, announced today that life sciences companies in the U.S. raised $25 million through activity of nine ATM offerings of common stock in the third quarter of this year.
|
|
|
|
 |
|
Endocyte Announces Results of Supplemental Analyses of PRECEDENT Trial
Date: December 12, 2011
Client: Endocyte, Inc.
Summary: WEST LAFAYETTE, Ind., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the results of supplemental analyses of its Phase 2b PRECEDENT trial. PRECEDENT was a randomized trial of EC145 in combination with pegylated liposomal doxorubicin (PLD) in women with platinum-resistant ovarian cancer. Results confirmed the reliability of its companion imaging diagnostic EC20 to select targeted patients. In addition, the blinded independent review committee (IRC) and numerous sensitivity analyses confirmed the robustness of the progression-free survival (PFS) results, particularly in the FR(++) patient population, patients whose tumors are all positive for the targeted folate receptor. The overall survival results were inconclusive as the trial was not sufficiently powered to show an overall survival advantage and there was no trend toward benefit in either arm.
|
|
|
|
 |
|
Abbott Labs Licenses Molecules from Reata
Date: December 12, 2011
Client: Reata Pharmaceuticals
Summary: Abbott Laboratories is paying $400 million to Reata Pharmaceuticals Inc. for rights to molecules showing early promise treating chronic diseases like rheumatoid arthritis and multiple sclerosis, the companies said Sunday.
|
|
|
|
 |
|
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients with Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
Date: December 12, 2011
Client: S*BIO
Summary: SINGAPORE, Dec. 12, 2011 - S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.
|
|
|
|
 |
|
Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
Date: December 12, 2011
Client: Regulus Therapeutics Inc.
Summary: LA JOLLA, Calif., Dec. 12, 2011 - Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment of glioblastoma multiforme (GBM), the most common and aggressive brain tumor in humans. Regulus will apply its expertise in microRNA therapeutics to discover chemically modified oligonucleotide anti-miRs for testing at the Samsung Medical Center in preclinical models that mimic human brain cancer. Accelerate Brain Cancer Cure (ABC2), a non-profit organization dedicated to accelerating therapies for brain cancer patients, has awarded Regulus a grant to support the research.
|
|
|
|
 |
|
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators
Date: December 12, 2011
Client: Reata Pharmaceuticals
Summary: Abbott Park, Ill. and Irving, Texas, December 12, 2011 - Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two companies announced in September 2010 in which Reata granted to Abbott exclusive rights to develop and commercialize its lead AIM compound, bardoxolone methyl, outside of the United States, excluding certain Asian markets.
|
|
|
|
 |
|
TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting
Date: December 11, 2011
Client: TetraLogic Pharmaceuticals
Summary: MALVERN, Pa., Dec. 11, 2011 - TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego. The study, conducted at The University of Texas M. D. Anderson Cancer Center, demonstrated that TL32711 induces apoptosis in acute myeloid leukemia (AML) cells, including AML stem/progenitor cells, alone and in combination with chemotherapy.
|
|
|
|
 |
|
ACT Announces Two New Appointments To Board Of Directors
Date: December 6, 2011
Client: Advanced Cell Technology, Inc.
Summary: MARLBOROUGH, Mass. - December 6, 2011 - Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Gregory D. Perry and Zohar Loshitzer have been appointed to the company's Board of Directors, effective today.
|
|
|
|
|
|
Data Published in EuroIntervention Indicate that OrbusNeich's Genous Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy
Date: December 5, 2011
Client: OrbusNeich
Summary: HONG KONG, Dec. 5, 2011 - OrbusNeich today announced that data published in the November issue of EuroIntervention indicate that the Genous Stent is safe when accompanied by only 10 days of dual antiplatelet therapy (DAPT).
|
|
|
|
|
